These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3953608)

  • 1. ASHP congressional testimony on the "gray market" in pharmaceuticals.
    Am J Hosp Pharm; 1986 Feb; 43(2):426-9. PubMed ID: 3953608
    [No Abstract]   [Full Text] [Related]  

  • 2. ASHP technical assistance bulletin on institutional use of controlled substances.
    Am J Hosp Pharm; 1987 Mar; 44(3):580-9. PubMed ID: 3565417
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-diversion turf war: will Cardinal ruling reinvent roles, DEA strategy?
    Lee J
    Mod Healthc; 2012 Mar; 42(10):8-9. PubMed ID: 22458066
    [No Abstract]   [Full Text] [Related]  

  • 4. Congress prepares laws to halt drug diversion.
    Wilkinson R
    Hospitals; 1986 Feb; 60(3):64. PubMed ID: 3943821
    [No Abstract]   [Full Text] [Related]  

  • 5. Should a registered pharmacist sign P.O. for a controlled drug?
    Decker R
    Hosp Purch Manage; 1981 Aug; 6(8):16. PubMed ID: 10252238
    [No Abstract]   [Full Text] [Related]  

  • 6. Can the Food and Drug Administration ensure that our pharmaceuticals are safely manufactured?
    Hubbard WK
    Arch Intern Med; 2009 Oct; 169(18):1655-6. PubMed ID: 19822821
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicine's "gray market"': why alarm bells are ringing.
    Gest T; Lanier LK
    US News World Rep; 1985 Dec; 99(23):52. PubMed ID: 10274713
    [No Abstract]   [Full Text] [Related]  

  • 8. ASHP guidelines on hospital drug distribution and control (with references).
    Am J Hosp Pharm; 1980 Aug; 37(8):1097-103. PubMed ID: 7405941
    [No Abstract]   [Full Text] [Related]  

  • 9. ASHP statement on hospital drug control systems.
    Am J Hosp Pharm; 1974 Dec; 31(12):1198-207. PubMed ID: 4458439
    [No Abstract]   [Full Text] [Related]  

  • 10. The prescription drug marketing act: a solution in search of a problem?
    Angarola RT; Beach JE
    Food Drug Law J; 1996; 51(1):21-55. PubMed ID: 11794352
    [No Abstract]   [Full Text] [Related]  

  • 11. Adequate controls for new drugs: good manufacturing practice and the 1938 federal Food, Drug, and Cosmetic Act.
    Cooper DE
    Pharm Hist; 2002; 44(1):12-23. PubMed ID: 12068915
    [No Abstract]   [Full Text] [Related]  

  • 12. ASHP statement on the pharmacist's responsibility for distribution and control of drug products.
    Am J Hosp Pharm; 1992 Aug; 49(8):2009-10. PubMed ID: 1442848
    [No Abstract]   [Full Text] [Related]  

  • 13. Criminal conviction for distribution of a drug not approved by the FDA.
    Brushwood DB
    Am J Hosp Pharm; 1991 Apr; 48(4):747-9. PubMed ID: 2042679
    [No Abstract]   [Full Text] [Related]  

  • 14. A sick agency in need of a cure? Recall of a popular pain drug has focused attention on government drug regulation.
    Spake A
    US News World Rep; 2004 Dec; 137(21):32-3, 36. PubMed ID: 15636503
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical product integrity: can the FDA assure quality?
    Bernstein I
    Manag Care; 2004 Mar; 13(3 Suppl):30-3. PubMed ID: 15074168
    [No Abstract]   [Full Text] [Related]  

  • 16. What gastroenterologists should know about the gray market, herbal remedies, and compounded pharmaceuticals and their regulation by the Food and Drug Administration.
    Ehrenpreis ED; Kulkarni P; Burke C;
    Am J Gastroenterol; 2013 May; 108(5):642-6. PubMed ID: 23644956
    [No Abstract]   [Full Text] [Related]  

  • 17. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM
    Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
    [No Abstract]   [Full Text] [Related]  

  • 18. How to crack the $2 billion hospital market for pharmaceuticals.
    Zellmer WA
    Med Mark Media; 1981 May; 16(5):16, 24. PubMed ID: 10251527
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA, industry collaborate to strengthen painkiller restrictions.
    Sipkoff M
    Manag Care; 2009 Apr; 18(4):10-1. PubMed ID: 19472560
    [No Abstract]   [Full Text] [Related]  

  • 20. The FDA and congress: differing agendas?
    Lipman AG
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):116-7. PubMed ID: 20504131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.